CD84 is markedly up-regulated in Kawasaki disease arteriopathy
R Reindel1, J Bischof, K-Y A Kim
1Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, USA.
Insights
Kawasaki disease (KD) causes persistent inflammation in coronary arteries (CA). Researchers found the CD84 molecule significantly increased in KD CA, indicating potential new therapeutic targets for this childhood illness.
Area of Science:
- Cardiovascular Research
- Immunology
- Molecular Biology
Background:
- Kawasaki disease (KD) is a critical pediatric illness affecting coronary arteries (CA).
- Current KD therapies aim to reduce inflammation and prevent thrombosis but are not universally effective.
- The unknown molecular pathogenesis of KD hinders the development of novel treatments.
Purpose of the Study:
- To identify dysregulated gene expression in KD CA.
- To investigate the role of specific molecules in KD pathogenesis.
- To provide molecular evidence for persistent inflammation in KD-affected CA.
Main Methods:
- High-throughput RNA sequencing of KD and control CA.
- Validation of gene expression using real-time reverse transcription-polymerase chain reaction (RT-PCR).
- Immunohistochemistry to localize protein expression in tissues.
Main Results:
- Signalling lymphocyte activation molecule CD84 was significantly upregulated in both acute (16-fold) and chronic (32-fold) KD CA.
- CD84 was localized to inflammatory cells within KD tissues.
- Genes related to cellular proliferation, motility, survival, and immune activation (MX2, SP140) were also upregulated in KD CA.
Conclusions:
- CD84 is markedly upregulated in KD CA, playing a role in immune responses and platelet stabilization.
- This study provides the first molecular evidence of sustained dysregulated inflammatory responses in CA damaged by KD.
- Findings suggest CD84 as a potential therapeutic target for Kawasaki disease.
Abstract:
The major goals of Kawasaki disease (KD) therapy are to reduce inflammation and prevent thrombosis in the coronary arteries (CA), but some children do not respond to currently available non-specific therapies. New treatments have been difficult to develop because the molecular pathogenesis is unknown. In order to identify dysregulated gene expression in KD CA, we performed high-throughput RNA sequencing on KD and control CA, validated potentially dysregulated genes by real-time reverse transcription-polymerase chain reaction (RT-PCR) and localized protein expression by immunohistochemistry. Signalling lymphocyte activation molecule CD84 was up-regulated 16-fold (P < 0·01) in acute KD CA (within 2 months of onset) and 32-fold (P < 0·01) in chronic CA (5 months to years after onset). CD84 was localized to inflammatory cells in KD tissues. Genes associated with cellular proliferation, motility and survival were also up-regulated in KD CA, and immune activation molecules MX2 and SP140 were up-regulated in chronic KD. CD84, which facilitates immune responses and stabilizes platelet aggregates, is markedly up-regulated in KD CA in patients with acute and chronic arterial disease. We provide the first molecular evidence of dysregulated inflammatory responses persisting for months to years in CA significantly damaged by KD.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Rheumatic Heart Disease I: Introduction
The JAK-STAT Signaling Pathway
Coronary Artery Disease II: Pathophysiology


